AU2002231139A1 - Thiazolyl inhibitors of tec family tyrosine kinases - Google Patents

Thiazolyl inhibitors of tec family tyrosine kinases

Info

Publication number
AU2002231139A1
AU2002231139A1 AU2002231139A AU2002231139A AU2002231139A1 AU 2002231139 A1 AU2002231139 A1 AU 2002231139A1 AU 2002231139 A AU2002231139 A AU 2002231139A AU 2002231139 A AU2002231139 A AU 2002231139A AU 2002231139 A1 AU2002231139 A1 AU 2002231139A1
Authority
AU
Australia
Prior art keywords
thiazolyl
inhibitors
tyrosine kinases
tec family
family tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002231139A
Other versions
AU2002231139B2 (en
Inventor
Joel C. Barrish
Jagabandhu Das
Arthur M.P. Doweyko
Joseph A. Furch
Steven B. Kanner
Chunjian Liu
Steven H. Spergel
John Witayk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority claimed from PCT/US2001/049430 external-priority patent/WO2002050071A1/en
Publication of AU2002231139A1 publication Critical patent/AU2002231139A1/en
Application granted granted Critical
Publication of AU2002231139B2 publication Critical patent/AU2002231139B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002231139A 2000-12-21 2001-12-19 Thiazolyl inhibitors of tec family tyrosine kinases Ceased AU2002231139B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25783000P 2000-12-21 2000-12-21
US60/257,830 2000-12-21
PCT/US2001/049430 WO2002050071A1 (en) 2000-12-21 2001-12-19 Thiazolyl inhibitors of tec family tyrosine kinases

Publications (2)

Publication Number Publication Date
AU2002231139A1 true AU2002231139A1 (en) 2002-09-05
AU2002231139B2 AU2002231139B2 (en) 2007-03-22

Family

ID=22977933

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002231139A Ceased AU2002231139B2 (en) 2000-12-21 2001-12-19 Thiazolyl inhibitors of tec family tyrosine kinases
AU3113902A Pending AU3113902A (en) 2000-12-21 2001-12-19 Thiazolyl inhibitors of tec family tyrosine kinases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3113902A Pending AU3113902A (en) 2000-12-21 2001-12-19 Thiazolyl inhibitors of tec family tyrosine kinases

Country Status (13)

Country Link
US (6) US6706717B2 (en)
EP (1) EP1347971B1 (en)
JP (1) JP4405726B2 (en)
AT (1) ATE318812T1 (en)
AU (2) AU2002231139B2 (en)
CA (1) CA2433018A1 (en)
CY (1) CY1105349T1 (en)
DE (1) DE60117605T2 (en)
DK (1) DK1347971T3 (en)
ES (1) ES2257461T3 (en)
HU (1) HUP0303538A2 (en)
PT (1) PT1347971E (en)
WO (1) WO2002050071A1 (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
EP1345916A1 (en) * 2000-12-20 2003-09-24 Glaxo Group Limited Substituted oxazoles and thiazoles as hppar alpha agonists
AU2002231139B2 (en) * 2000-12-21 2007-03-22 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
DE10110747A1 (en) 2001-03-07 2002-09-12 Bayer Ag Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use
WO2004014904A1 (en) * 2002-08-09 2004-02-19 Pfizer Inc. Antiproliferative 2-(heteroaryl)-aminothiazole compounds, pharmaceutical compositions and methods for their use
SE0202464D0 (en) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
AU2003285007A1 (en) * 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2004220113A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company Opioid receptor antagonists
AR045047A1 (en) * 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
KR20060056944A (en) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
ATE485300T1 (en) 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc THIENOPYRIMIDINES USABLE AS AURORA KINASE INHIBITORS
DE102004042607A1 (en) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituted phenylaminothiazoles and their use
EP1831168B1 (en) * 2004-12-16 2014-07-02 Vertex Pharmaceuticals Inc. Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
CA2595834C (en) 2005-02-04 2013-04-30 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
CA2618646A1 (en) * 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
JP2009513615A (en) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 4- (3-Aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CA2633569A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
CN101346361A (en) * 2005-12-22 2009-01-14 阿斯利康(瑞典)有限公司 Chemical compounds
US8034954B2 (en) * 2005-12-22 2011-10-11 Icagen, Inc. Calcium channel antagonists
EP2027087A2 (en) * 2006-05-18 2009-02-25 MannKind Corporation Intracellular kinase inhibitors
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
DE102006042143A1 (en) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Novel substituted bipyridine derivatives and their use
DE102006044696A1 (en) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-cyano-5-thiazaheteroaryl-dihydropyridines and their use
CA2669704A1 (en) * 2006-11-16 2008-05-22 Allergan, Inc. Sulfoximines as kinase inhibitors
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
DE102006056740A1 (en) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclic substituted 3,5-dicyano-2-thiopyridines and their use
DE102006056739A1 (en) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituted 4-amino-3,5-dicyano-2-thiopyridines and their use
US8148400B2 (en) * 2006-12-20 2012-04-03 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors
EP2111402B1 (en) * 2007-01-05 2012-03-07 Bristol-Myers Squibb Company Aminopyrazole kinase inhibitors
CN101679406B (en) 2007-04-10 2013-07-10 百时美施贵宝公司 Thiazolyl compounds useful as kinase inhibitors
DE102007035367A1 (en) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituted aryloxazoles and their use
DE102007036076A1 (en) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid Produgs and their use
CA2695517C (en) 2007-08-03 2016-09-20 J. Edward Semple Alkylsulfonyl-substituted thiazolide compounds
AU2008310097B2 (en) 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
DE102007061764A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellated cyanopyridines and their use
DE102007061763A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted azabicyclic compounds and their use
DE102008013587A1 (en) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituted dicyanopyridines and their use
US8791146B2 (en) 2008-05-29 2014-07-29 Bayer Intellectual Property Gmbh 2-alkoxy-substituted dicyanopyridines and their use
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
HUE043569T2 (en) 2008-06-16 2019-08-28 Univ Tennessee Res Found Compounds for the treatment of cancer
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
DE102008062567A1 (en) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid prodrugs and their use
DE102009006602A1 (en) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
CN105853415A (en) * 2009-05-12 2016-08-17 罗马克实验室有限公司 Haloalkyl heteroaryl benzamide compounds
CA2968113C (en) 2009-06-26 2019-05-14 Romark Laboratories L.C. Compounds and methods for treating influenza
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
JP5836280B2 (en) 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド Treatment of Attention Deficit / Hyperactivity Disorder (ADHD)
BR112012010648A2 (en) 2009-11-06 2020-12-01 Sk Biopharmaceuticals Co., Ltd. use of compounds in the preparation of pharmaceutical compositions to treat fibromyalgia syndrome and pharmaceutical composition
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR20120130777A (en) * 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CA2798514A1 (en) 2010-05-12 2011-11-17 P. Jeffrey Conn Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
DE102010030688A1 (en) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituted dicyanopyridines and their use
ES2718637T3 (en) * 2010-08-24 2019-07-03 Gtx Inc Compounds for cancer treatment
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
CN103221410B (en) 2010-09-22 2017-09-15 艾尼纳制药公司 GPR119 receptor modulators and the treatment to relative obstacle
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103724349A (en) * 2012-10-11 2014-04-16 韩冰 Compound for treating cerebral palsy and use thereof
CN104003956A (en) * 2013-02-27 2014-08-27 中国药科大学 Thiazole compound, preparation method thereof and application in pharmacy
AU2014225761B2 (en) 2013-03-05 2018-06-07 University Of Tennessee Research Foundation Compounds for treatment of cancer
JO3377B1 (en) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co Pyridinyl and fused pyridinyl triazolone derivatives
KR101793807B1 (en) 2013-04-25 2017-11-03 베이진 엘티디 Fused heterocyclic compounds as protein kinase inhibitors
EP4130044A1 (en) 2013-09-13 2023-02-08 BeiGene Switzerland GmbH Anti-pd1 antibodies and their use as therapeutics and diagnostics
EP3060218A4 (en) 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
AU2015240518A1 (en) * 2014-04-05 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2948334A1 (en) 2014-05-06 2015-11-12 Gtx, Inc. Benzimidazole and imidazo[4,5]pyridine compounds for the treatment of cancer
KR102130600B1 (en) 2014-07-03 2020-07-08 베이진 엘티디 Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Crystalline free-plate habit of l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid
CN105017174B (en) * 2015-07-13 2017-03-15 南华大学 N‑（4 alkyl, 5 benzyl thiazole, 2 base）Acrylamide and preparation method and application
EP3344254A1 (en) 2015-08-31 2018-07-11 Pharmacyclics LLC Btk inhibitor combinations for treating multiple myeloma
AU2016319125B2 (en) * 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
TWI620748B (en) * 2016-02-05 2018-04-11 National Health Research Institutes Aminothiazole compounds and use thereof
AU2017240609B2 (en) 2016-03-31 2021-07-15 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
AU2017293423B2 (en) 2016-07-05 2023-05-25 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
IL292938A (en) 2016-09-19 2022-07-01 Mei Pharma Inc Combination therapy
JOP20190052A1 (en) * 2016-09-22 2019-03-21 Astrazeneca Ab 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma
MX2019005029A (en) 2016-11-03 2019-10-24 Juno Therapeutics Inc Combination therapy of a t cell therapy and a btk inhibitor.
JP7236996B2 (en) * 2016-11-03 2023-03-10 コーバス・ファーマシューティカルズ・インコーポレイテッド Compounds and methods that modulate interleukin-2-induced T cell kinase
JP7077335B2 (en) 2016-12-13 2022-05-30 プリンストン ドラッグ ディスカバリー インコーポレイテッド Protein kinase inhibitor
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
JP2020507611A (en) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Compounds and methods for the treatment of primary biliary cholangitis
CA3066518A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
KR102384924B1 (en) 2017-07-12 2022-04-08 주식회사 대웅제약 Novel 1h-pyrazolopyridin derivatives and pharmaceutical composition comprising the same
WO2019013562A1 (en) 2017-07-12 2019-01-17 주식회사 대웅제약 Novel 1h-pyrazolopyridine derivative and pharmaceutical composition containing same
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY
KR102613433B1 (en) 2017-10-11 2023-12-13 주식회사 대웅제약 Novel phenyl pyridine derivatives and pharmaceutical composition comprising the same
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
AU2019261986A1 (en) 2018-05-03 2020-11-26 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (CAR) T cell therapy and a kinase inhibitor
WO2020045941A1 (en) 2018-08-27 2020-03-05 주식회사 대웅제약 Novel heterocyclic amine derivative and pharmaceutical composition comprising same
CN115151537A (en) 2020-02-26 2022-10-04 株式会社大熊制药 Process for preparing heterocyclic amine derivatives
WO2021262636A2 (en) * 2020-06-23 2021-12-30 Dana-Farber Cancer Institute, Inc. Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649146A (en) 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
TW205041B (en) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
FR2742153B1 (en) * 1995-12-12 1998-02-13 Innothera Lab Sa USE OF TRICYCLIC DERIVATIVES OF 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTALENE, NEW COMPOUNDS OBTAINED AND THEIR THERAPEUTIC APPLICATION
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP0928790B1 (en) 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives
SI0928793T1 (en) 1998-01-02 2002-10-31 F. Hoffmann-La Roche Ag Thiazole derivatives
CA2332325A1 (en) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
JP2002520324A (en) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド Novel angiogenesis inhibitors
WO2000017175A1 (en) 1998-09-18 2000-03-30 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
CZ20011395A3 (en) 1998-10-22 2001-08-15 F. Hoffmann-La Roche Ag Thiazole derivatives
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
JP3498600B2 (en) 1998-11-09 2004-02-16 三菱電機株式会社 Carrier phase estimator and demodulator using carrier phase estimator
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
BRPI0009721B1 (en) * 1999-04-15 2018-11-21 Bristol-Myers Squibb Holdings Ireland cyclic protein tyrosine kinase inhibitors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
ATE309241T1 (en) * 1999-09-10 2005-11-15 Merck & Co Inc TYROSINE KINASE INHIBITORS
SE9904177D0 (en) 1999-11-18 1999-11-18 Astra Ab Novel compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2002231139B2 (en) 2000-12-21 2007-03-22 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases

Similar Documents

Publication Publication Date Title
AU2002231139A1 (en) Thiazolyl inhibitors of tec family tyrosine kinases
AU2002213485A1 (en) Inhibitors of protein kinases
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
AU2001241927A1 (en) Inhibitors of p38-alpha kinase
AU2002256418A1 (en) Inhibitors of bace
AU2679099A (en) Methods for designing inhibitors of serine/threonine kinases and tyrosine kinases
AU2003282891A1 (en) Novel tyrosine kinases inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
HK1160859A1 (en) Inhibitors of tyrosine kinases
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU5316900A (en) Inhibitors of c-jun n-terminal kinases (jnk)
AU2002357193A1 (en) Thienopyrimidine compounds as protein tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2002343356A1 (en) Antisense modulation of protein kinase r expression
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002256085A1 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2002237657A1 (en) Indole-type inhibitors of p38 kinase
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2002307996A1 (en) Mutants of desoxycytidine kinase having extended enzymatic activity
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
SI1347971T1 (en) Thiazolyl inhibitors of tec family tyrosine kinases